Uncontrolled hypertension—also known as high blood pressure—can increase the risk of stroke, heart attack, heart failure, and kidney disease. Heart disease and stroke are the two leading causes of American death.

According to the CDC, one in three US adults has high blood pressure—and only half of them have it under control. This creates long-term damage to the body’s arteries and heart, which in turn affects the brain, kidneys, and eyes.

High blood pressure is estimated to cost the US $48.6 billion annually. Since the early 90s, it has rapidly risen to be the number one contributing factor to life-threatening conditions like heart attack and stroke.

Existing medications like beta blockers don’t work for everyone, and can carry significant side effects. There is an urgent need for more treatment options for high blood pressure—which is where research studies can help.

Take the next step to see if you qualify for local research studies for people with hypertension. But don’t delay — space is limited!

Get started now

How does it work?

1

Tell us a little bit about yourself

2

Answer some questions about your health

3

We will connect you to available studies in your area

Just takes a few minutes

Get started now

COVID-19 update — we remain open.

For the safety of both staff and patients, we require that our research sites are COVID-19 SMART facilities. That means they use best practices to reduce virus exposure and are dedicated to ensuring they remain open and available for the research of investigational medications.

COVID-19 SMART steps we are taking to ensure safety include:

  • Greatly increased availability of video office visits
  • Ensuring social distancing measures are taken in all waiting areas
  • Continuing the practice of cleaning and disinfecting exams rooms thoroughly between every visit
  • Appropriate personal protective equipment (PPE) for all staff members at our health clinics

AcurianHealth helps connect people with research studies that offer treatment under development. Since 1998, AcurianHealth has referred 1 million study candidates to 800 studies in 70 countries.